Breaking down the lipids paradigm

Article 3 min read


Bookmark this story

Reported to play a detrimental role in health; oils, fats and lipids have been broadly stigmatised as detrimental and promoters of health conditions like obesity, cardiovascular disease, and even type-2-diabetes (T2D). However, the contribution of dietary lipids to an adequate – moreover- necessary nutrition, homeostasis, and assimilation of essential nutrients is crucial to human body. Furthermore, lipids deliver taste and indulgent properties to practically all the foods we consume.

In addition, beyond commonly known oils and fats, some other lipids play a very specific role in human biochemistry and have been proven bioactive in preventing and controlling metabolic disorders. In such a way, Alianza Team is leading applied research in lipid functionality and bioactivity in food and related categories; striving to deliver highly specialised lipid-based compositions for their clients in the food, personal care, and food supplement industries

Non-communicable diseases (NCDs) and their impact on social health

Chronic NCDs cause 63% of deaths worldwide and maybe categorised as a global pandemic. NCDs are mostly due to unbalanced diets, unbalanced lifestyles, or both. NCDs are boosted by main incident factors like smoking, sedentary, alcoholism and eating habits. These misconceived eating habits have become a usual pattern of a generalised modern lifestyle where healthy food is scarce and expensive. The whole situation happens to be now a global health issue that has led to alterations in metabolism, irrespective of social status race or geography.

T2D is one of the main causes of morbidity and mortality worldwide. T2D is preceded by metabolic alterations which, in context, are known as “prediabetes” , a definition that encompasses impaired glucose tolerance, impaired fasting glucose and elevated levels of glycated haemoglobin A1c that do not reach the threshold for manifest diabetes (American Diabetes Association, 2017).

Despite pharmacological treatments and insulin therapies aimed at controlling T2D and its associated symptoms, the dietary proposals and dietary supplements on the market are hardly accessible and poorly effective in the treatment of T2D. Therefore, natural, low calorie solutions designed from applied science, are required. These types of solutions can be more effective and have a greater impact when the disease is still in its early stages (prediabetes).

A novel lipid-based dietary composition for prevention and control of T2D

Non-communicable diseases are directly influenced by inappropriate diet and living habits. This fact makes it necessary that practical, affordable, and effective solutions come from the food industry. Alianza Team has recently developed a 100% natural lipid-based bioactive composition with benefits of prevention and control on insulin resistance and associated disturbances in T2D (Mendivil, Carlos O., et al., Impact of a Formulation Containing Unusual Polyunsaturated Fatty Acids, Trace Elements, Polyphenols and Plant Sterols on Insulin Resistance and Associated Disturbances. Universidad de Los Andes, Bogota-Colombia. Diabetes Therapy, 2019). The invention is the first available for commercialisation within the Lipids & Health innovation platform of Alianza Team, and is part of a complete set of upcoming innovations including natural lipid-based solutions for cognitive impairment, cardiovascular disease, fatty liver disease, depression, immunity and gastro-intestinal health. Other innovation platforms in Alianza Team include contaminant-free edible oils and structured lipids for infant formulae.

Alianza Team’s core competence is R&D, which focusses on the domain of applied lipid science and technology into practical products. The bioactive effects of dietary lipids, particularly, lipids and their effects on T2D associated metabolic pathways, led to this novel product which was tested (proof-of-concept test) at preclinical level.

The study involved measurements of responsive blood parameters: glycaemic response, insulinemia, inflammatory profile, hepatic profile, toxicological evaluation, renal impact, Lipid profile, as well as hormone response and anthropometric measures.

As a conclusion, the product exhibited these positive effects: Insulin resistance and sensitivity, reduced low-grade inflammation, decreased number of liver-damaged cells, improved blood cholesterol profiles, increased thermogenesis.

The product, in powder form, maybe used as a dietary supplement (one single daily dose of 9 grams, dispersible in water), or to be added as an ingredient in food product categories (i.e., dairy products). Not only the design characteristics and health properties of this invention but also the different possibilities of application in the food industry makes this invention (under patent application) a novel and effective option in the prevention and control of T2D, that offers a natural alternative to consumers.

This invention represents a novel, innovative approach to reduce global NCDs pandemics from the food industry perspective. It is a new frontier in the practical application of novel lipids in the design of nutraceuticals, supplements, and functional food.

Alianza Team is moving forward to offering international consumers the opportunity to try this innovation. Furthermore, Alianza Team is looking for partners in the supplement or functional food sectors, whose strategy is oriented to take to market natural bioactive dietary products into their brands. Alianza Team is, therefore, open to discuss partnership scenarios which may include: a base supplier-client relationship, investment in clinical trials for further registration of a finished product / brand as a medical device, technology transfer, or some others. For any further questions or more information, interested parties may contact: Daniel Colmenares. R&D Director

Related articles:

Has COVID-19 threatened to de-stabilise the clean label movement?
UK Government introduces New Obesity Strategy to improve public health
Navigating the changing consumer behaviours post Covid-19